argenx SE (NASDAQ:ARGX) Shares Bought by Wilmington Savings Fund Society FSB

Wilmington Savings Fund Society FSB lifted its position in shares of argenx SE (NASDAQ:ARGX) by 47.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,776 shares of the company’s stock after purchasing an additional 574 shares during the period. Wilmington Savings Fund Society FSB’s holdings in argenx were worth $1,092,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Advisors Preferred LLC acquired a new position in argenx in the 4th quarter worth $73,000. Cromwell Holdings LLC increased its position in shares of argenx by 73.3% during the third quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after acquiring an additional 66 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of argenx by 47.5% in the third quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock worth $94,000 after acquiring an additional 56 shares in the last quarter. Blue Trust Inc. boosted its holdings in argenx by 413.9% in the third quarter. Blue Trust Inc. now owns 370 shares of the company’s stock valued at $201,000 after purchasing an additional 298 shares during the last quarter. Finally, Keudell Morrison Wealth Management purchased a new stake in argenx during the 3rd quarter worth approximately $207,000. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenx Stock Performance

argenx stock opened at $646.45 on Tuesday. argenx SE has a one year low of $349.86 and a one year high of $678.21. The company has a 50-day simple moving average of $637.69 and a 200-day simple moving average of $578.86. The firm has a market capitalization of $39.28 billion, a P/E ratio of -734.60 and a beta of 0.58.

Analyst Upgrades and Downgrades

ARGX has been the subject of several research analyst reports. JMP Securities increased their target price on argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a research note on Tuesday, January 14th. Piper Sandler increased their price objective on shares of argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a research note on Tuesday, January 7th. Baird R W downgraded shares of argenx from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 1st. Wells Fargo & Company increased their price target on shares of argenx from $639.00 to $723.00 and gave the stock an “overweight” rating in a research report on Thursday, December 19th. Finally, Citigroup boosted their price objective on argenx from $512.00 to $635.00 and gave the company a “buy” rating in a report on Thursday, October 17th. One analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $658.39.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.